Bradley Tandy Acquires 3,200 Shares of Enovis (NYSE:ENOV) Stock

Key Points

• SVP Bradley Tandy purchased 3,200 shares of Enovis at an average price of $31.41, increasing his ownership by 7.94% and bringing his total shares to 43,515.
• Enovis reported earnings of $0.79 per share for the last quarter, surpassing analyst expectations, and the company anticipates an EPS of 2.79 for the current fiscal year.
• Analysts have recently adjusted their price targets for Enovis, with estimates ranging from $41.00 to $57.00, reflecting a consensus target price of $51.00.

Enovis Corporation (NYSE:ENOV - Get Free Report) SVP Bradley Tandy purchased 3,200 shares of the stock in a transaction dated Friday, August 22nd. The shares were purchased at an average price of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president owned 43,515 shares of the company's stock, valued at approximately $1,366,806.15. This trade represents a 7.94% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Enovis Trading Up 6.5%

NYSE:ENOV opened at $31.4080 on Monday. The firm has a market cap of $1.80 billion, a PE ratio of -2.20 and a beta of 1.70. The stock has a fifty day moving average price of $30.06 and a 200 day moving average price of $33.93. Enovis Corporation has a 12-month low of $25.47 and a 12-month high of $49.83. The company has a current ratio of 2.25, a quick ratio of 1.15 and a debt-to-equity ratio of 0.53.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.05. The firm had revenue of $564.50 million during the quarter, compared to analyst estimates of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.Enovis's revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.62 earnings per share. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. Sell-side analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on ENOV shares. UBS Group decreased their price target on Enovis from $65.00 to $57.00 and set a "buy" rating for the company in a report on Friday, August 8th. Wells Fargo & Company decreased their price target on Enovis from $48.00 to $41.00 and set an "overweight" rating for the company in a report on Friday, August 8th. Evercore ISI decreased their price target on Enovis from $48.00 to $46.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Canaccord Genuity Group cut their target price on Enovis from $70.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $51.00.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently made changes to their positions in ENOV. Farther Finance Advisors LLC increased its position in Enovis by 266.7% in the 1st quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock valued at $27,000 after acquiring an additional 536 shares during the period. Quarry LP increased its position in Enovis by 506.1% in the 4th quarter. Quarry LP now owns 897 shares of the company's stock valued at $39,000 after acquiring an additional 749 shares during the period. EverSource Wealth Advisors LLC increased its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC increased its position in Enovis by 144.8% in the 1st quarter. GAMMA Investing LLC now owns 1,170 shares of the company's stock valued at $45,000 after acquiring an additional 692 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in Enovis in the 2nd quarter valued at about $46,000. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.